Hematologic Cancers News

Duvelisib Delayed Progression in CLL/SLL: Study

Duvelisib Delayed Progression in CLL/SLL: Study

Duvelisib improved PFS by more than 3 months compared with ofatumumab, the current standard of care, in relapsed or refractory CLL and SLL.

Investigators Report the Successful Allogeneic Transfer of Cytotoxic T Lymphocytes in Progressive Multifocal Leukoencephalopathy

Investigators Report the Successful Allogeneic Transfer of Cytotoxic T Lymphocytes in Progressive Multifocal Leukoencephalopathy

BK-virus-specific T cells from a third-party donor were shown to successfully clear a related virus known to cause PML in 3 patients with different conditions.

Dasatinib in Chronic Myeloid Leukemia Linked to Higher Healthcare Costs

Dasatinib in Chronic Myeloid Leukemia Linked to Higher Healthcare Costs

Increased costs were found to be a result of more infections.

Fecal Transplantation Restores Patient Gut Microbiota Following Allo-HSCT

Fecal Transplantation Restores Patient Gut Microbiota Following Allo-HSCT

After antibiotic treatment during allogeneic hematopoietic stem cell transplantation, fecal transplantation was shown to restore patients' gut microbiota.

Pilot Study Supports Lower Dose of Ibrutinib in Chronic Lymphocytic Leukemia

Pilot Study Supports Lower Dose of Ibrutinib in Chronic Lymphocytic Leukemia

In patients with chronic lymphocytic leukemia, a lower ibrutinib dose appears to confer sufficient biological activity, but further study is needed.

Multigene Panel Testing May Guide Diagnosis and Management of Hereditary Anemia

Multigene Panel Testing May Guide Diagnosis and Management of Hereditary Anemia

The overlapping phenotypes of many hereditary anemias can make differential diagnosis and classification very difficult,

Hemophilic Joint Bleeding Promotes Vascular Remodeling, Rebleeding Independent of Hemostatic Correction

Hemophilic Joint Bleeding Promotes Vascular Remodeling, Rebleeding Independent of Hemostatic Correction

Hemophilic joint bleeding often leads to aberrant expression of alpha-smoot muscle actin, which can indicate vascular remodeling.

Subcutaneous Emicizumab Effectively Prevents Bleeding in Patients With Hemophilia A

Subcutaneous Emicizumab Effectively Prevents Bleeding in Patients With Hemophilia A

Emicizumab prophylaxis provides effective bleed prevention in people with hemophilia A with and without inhibitors.

Novel, von Willebrand factor-independent FVIII Therapy May Allow for Weekly Dosing

Novel, von Willebrand factor-independent FVIII Therapy May Allow for Weekly Dosing

A novel, von Willebrand factor-independent factor VIII therapy may allow patients with severe hemophilia A to pursue weekly dosing.

Inhibitor Incidence Is Similar for Recombinant, Plasma-Derived FVIII Treatment Products

Inhibitor Incidence Is Similar for Recombinant, Plasma-Derived FVIII Treatment Products

The study confirmed that recombinant and plasma-derived FVIII treatment products are associated with similar risk.

Philipp Tool Demonstrates Low Utility in Assessing Heavy Menstrual Bleeding for a Hemostatic Defect

Philipp Tool Demonstrates Low Utility in Assessing Heavy Menstrual Bleeding for a Hemostatic Defect

Although anovulation is the most common cause of heavy menstrual bleeding, an underlying hemostatic defect may also contribute to this menstrual problem.

Leukemic Cells in CAR-T Find a New Way to Evade Immune Recognition

Leukemic Cells in CAR-T Find a New Way to Evade Immune Recognition

Standard flow cytometry missed the detection of the CAR19 epitope on the surface of the leukemia cells.

Whole-Body CT Influenced the Management of Myeloma and Precursor Diseases

Whole-Body CT Influenced the Management of Myeloma and Precursor Diseases

The use of low-dose WBCT in multiple myeloma provided important information that helped guide patient management in 97% of the cases that were reviewed.

Rituximab Did Not Reduce Acute iTTP Relapses in Retrospective Observational Study

Rituximab Did Not Reduce Acute iTTP Relapses in Retrospective Observational Study

The use of rituximab for autoimmune thrombotic thrombocytopenic purpura did not significantly reduce acute iTTP relapses.

Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment

Baseline Thrombopoietin Levels May Help Predict Response to ITP Treatment

Results of the retrospective study require further confirmation.

Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed

Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed

First-degree relatives of patients with multiple myeloma were found to be at a higher risk of developing monoclonal gammopathy of undetermined significance.

Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma

Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma

Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.

Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia

Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia

The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.

Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia

Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia

Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs